AZD3470
Small molecule
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other PRMT5 drugs
BAY 3713372, TNG456, Vopimetostat, HSK41959, IDE892. Compare all 6 PRMT5 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| AZD3470: this drug | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| BAY 3713372 | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| TNG456 | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| Vopimetostat | Phase 1/2(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| HSK41959 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| IDE892 | Phase 1(overall) | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary | |
| Ralometostat | Discontinued | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow AZD3470 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.